Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 33Cisplatin 23Carboplatin 15Cetuximab 14Magnetic Resonance Spectroscopy 13Specimen Handling 10Radiotherapy, Intensity-Modulated 10Paclitaxel 9Platinum 8Nivolumab 81,2-diaminocyclohexaneplatinum II citrate 8Docetaxel 7atezolizumab 5Taxes 5Radiotherapy 5Biopsy 5Radiation 4Immunoglobulin G 4Fluorouracil 4Disulfides 4Bevacizumab 4(225)Ac-DOTA-c(RGDyK) 4dostarlimab 3cemiplimab 3Fulvestrant 3dehydroftorafur 2budigalimab 2amivantamab 2abemaciclib 2Tiragolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × nimotuzumab × 30 days × Clear all
NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
182 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡